Probiotics for the Prevention of Beta Cell Autoimmunity in Children at Genetic Risk of Type 1 Diabetes—the PRODIA Study

Authors

  • MARTIN LJUNGBERG,

    1. Division of Pediatrics and Diabetes Research Centre, Department of Molecular and Clinical Medicine, Linköping University, S-58 185 Linköping, Sweden
    Search for more papers by this author
  • RIITA KORPELA,

    1. Valio Ltd, 00037 Helsinki, Finland
    Search for more papers by this author
  • JORMA ILONEN,

    1. Department of Clinical Microbiology, University of Kuopio, Kuopio, Finland and Immunogenetics Laboratory, University of Turku, 20520 Turku, Finland
    Search for more papers by this author
  • JOHNNY LUDVIGSSON,

    1. Division of Pediatrics and Diabetes Research Centre, Department of Molecular and Clinical Medicine, Linköping University, S-58 185 Linköping, Sweden
    Search for more papers by this author
  • OUTI VAARALA

    1. Division of Pediatrics and Diabetes Research Centre, Department of Molecular and Clinical Medicine, Linköping University, S-58 185 Linköping, Sweden
    2. Department of Viral Diseases and Immunology, National Public Health Institute, 00037 Helsinki, Finland
    Search for more papers by this author

Address for correspondence: Martin Ljungberg, Centre of Clinical Experimental Research, Division of Pediatrics and Diabetes Research Centre, Department of Molecular and Clinical Medicine, Faculty of Health Sciences, Linköping University, S-581 85 Linköping, Sweden. Voice: +46-13-229538; fax: +46-13-127465.
 e-mail: martin.ljungberg@imk.liu.se

Abstract

Abstract: The final aim of the PRODIA study is to determine whether the use of probiotics during the first 6 months of life decreases the appearance of type 1 diabetes mellitus (T1DM)-associated autoantibodies in children with genetic risk for T1DM. A pilot study including 200 subjects was planned to show whether the use of probiotics during the first 6 months of life is safe and feasible. The prevalence of autoantibodies among the study subjects at 6, 12, and 24 months of age was at levels close to the expected and the clinical follow-up did not either indicate problems in the feasibility of the study.

Ancillary